Barbara G Fox

Array ( [id] => 13314289 [patent_doc_number] => 20180208681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN FUSION MOLECULES [patent_app_type] => utility [patent_app_number] => 15/921469 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15921469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15618907 [patent_doc_number] => 20200079858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => ANTIBODY CONJUGATE FOR TREATING AND DETECTING BLADDER CANCER [patent_app_type] => utility [patent_app_number] => 16/493845 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16493845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13955647 [patent_doc_number] => 20190054167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => METHOD FOR TREATING RHEUMATOID ARTHRITIS WITH A HUMAN IL-6 RECEPTOR ANTIBODY AND METHOTREXATE [patent_app_type] => utility [patent_app_number] => 15/919429 [patent_app_country] => US [patent_app_date] => 2018-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15919429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17118774 [patent_doc_number] => 11129883 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => IL-15-based fusions to IL-12 and IL-18 [patent_app_type] => utility [patent_app_number] => 15/913837 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 30 [patent_no_of_words] => 29930 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15913837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283753 [patent_doc_number] => 20200277355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => SELECTIVE TNFR1 ANTAGONIST PEPTIDE SN10 AND APPLICATION THEREOF IN INFLAMMATORY BOWEL DISEASE [patent_app_type] => utility [patent_app_number] => 16/496640 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360883 [patent_doc_number] => 20200016206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD USING AN INTERLEUKIN-2 RECEPTOR ALPHA, BETA-SELECTIVE AGONIST IN COMBINATION WITH ADOPTIVE CELL TRANSFER THERAPY [patent_app_type] => utility [patent_app_number] => 16/490443 [patent_app_country] => US [patent_app_date] => 2018-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16490443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175535 [patent_doc_number] => 20200222503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 16/484852 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15666457 [patent_doc_number] => 10597447 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Compositions comprising purified recombinant IL-13 antibody [patent_app_type] => utility [patent_app_number] => 15/902139 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 36767 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414528 [patent_doc_number] => 10822404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Methods and compositions comprising purified recombinant polypeptides [patent_app_type] => utility [patent_app_number] => 15/902145 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 36840 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522085 [patent_doc_number] => 20180312585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 15/902141 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13536631 [patent_doc_number] => 20180319859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS [patent_app_type] => utility [patent_app_number] => 15/901705 [patent_app_country] => US [patent_app_date] => 2018-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522053 [patent_doc_number] => 20180312569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => Oligomers for TNF Superfamily Inhibition, Methods of Making and Using [patent_app_type] => utility [patent_app_number] => 15/894502 [patent_app_country] => US [patent_app_date] => 2018-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15894502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428736 [patent_doc_number] => 11673946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Methods of treating a companion animal species comprising administering anti-IL31 antibodies [patent_app_type] => utility [patent_app_number] => 16/488045 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 19 [patent_no_of_words] => 20739 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 295 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16488045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371897 [patent_doc_number] => 20180237489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS [patent_app_type] => utility [patent_app_number] => 15/893451 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808684 [patent_doc_number] => 20180161398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => COMPOSITION CONTAINING INDUCER OF SIRT1 EXPRESSION FOR PREVENTING OR TREATING SEPSIS OR SEPTIC SHOCK [patent_app_type] => utility [patent_app_number] => 15/889393 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444145 [patent_doc_number] => 20180273615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 15/886277 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15886277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17307398 [patent_doc_number] => 11208491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody [patent_app_type] => utility [patent_app_number] => 16/480296 [patent_app_country] => US [patent_app_date] => 2018-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 22 [patent_no_of_words] => 18736 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16480296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16259883 [patent_doc_number] => 10751291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Nanoparticulate compositions comprising interferon gamma and losartan for immunotherapy [patent_app_type] => utility [patent_app_number] => 15/860888 [patent_app_country] => US [patent_app_date] => 2018-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 27433 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15860888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17467662 [patent_doc_number] => 11274130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => HV1 modulators and uses [patent_app_type] => utility [patent_app_number] => 16/474906 [patent_app_country] => US [patent_app_date] => 2017-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 35 [patent_no_of_words] => 21373 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16474906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147869 [patent_doc_number] => 20190352412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/472173 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16472173 [rel_patent_id] =>[rel_patent_doc_number] =>)